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RDichotomizing High-Sensitivity
Cardiac Troponin T Results
and Important Analytical
Considerations
We read with great interest the paper by Body et al. (1) that
presented intriguing data on a possible early rule-out protocol for
acute myocardial infarction in patients presenting with undetect-
able cardiac troponin T (cTnT) measured with the high-sensitivity
assay ([hs-cTnT], undetectable 3 ng/l). Using this approach,
nearly one-quarter of the population could be ruled out for acute
myocardial infarction at presentation with, the investigators con-
tend, possibly no need for serial troponin testing in this group (1).
However, at these lower concentrations, there are other important
factors, in addition to imprecision, that need to be considered.
First, there is no standardization in reporting hs-cTnT results,
with different laboratories using different cutoffs and lower limits
for reporting (e.g., limit of the blank [LoB]  3 ng/l, which Body
t al. used versus limit of detection  5 ng/l) (2). It would be
nteresting to see how this rule-out algorithm would change if the
igher limit of detection of 5 ng/l were used as opposed to the LoB
f 3 ng/l.
Second, the presence of hemolysis will also negatively affect
he cTnT concentrations, with larger concentrations of hemo-
lobin resulting in proportionally lower cTnT concentrations
3). This is not a trivial problem, as a recent audit in our
ospital over 1 month identified over 10% (217 of 2,085) of
TnT results were on hemolyzed samples. Thus, for hemolyzed
pecimens whose reported hs-cTnT concentrations are 3 ng/l,
a repeat specimen may be required to confirm that the cTnT
concentration is truly below the LoB and not due to this
negative interferent.
Third, this approach of using the LoB to rule out acute
myocardial infarction may not be transferable to other assays that
are perhaps more analytically sensitive. For example, in a cohort of
chest pain patients presenting early to an emergency department,
more than 25% of these patients had hs-cTnT concentrations
below the LoB; however, in contrast, all of these patients had
detectable cardiac troponin I concentrations as measured with an
investigational-use high-sensitivity cardiac troponin I assay (4). It
is clear from the work of Body et al. (1) that changes in how we use
and report high-sensitivity cardiac troponin assays are required to
achieve the most optimum care for patients presenting with chest
pain. However, the true benefit for early rule-out may be less than
reported after including other important outcomes requiring hos-
pital admission (i.e., all of the major adverse cardiac events) and
after considering important analytical issues.
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The D-Dimer Approach for
Troponin in the Diagnosis of
Myocardial Infarction
Is it Really Useful?
We read with interest the paper by Body et al. (1). In a cohort of
703 individuals with acute chest pain, Body et al. demonstrated
that the use of a high-sensitivity troponin assay coupled with a low
cutoff point (any detectable level) yields 100% sensitivity for
recognizing myocardial infarction, leading to a perfect negative
predictive value. Thus, the investigators concluded, “this strategy
could be used to reduce unnecessary hospital admissions.” We
intend to further analyze the implications of this approach.
First, in order to reduce the number of patients unnecessarily
admitted to the hospital, a test should have an improved ability to
recognize healthy individuals that can be safely discharged. The ability
to recognize healthy people is defined as “specificity.” As one lowers
the cutoff point of a test, sensitivity improves at the cost of specificity.
In fact, along with the increase in sensitivity from 85% to 100%, the
investigators reported a decrease in specificity from 82% to 34% as the
lower cutoff was adopted. Because a smaller number of healthy people
will be identified, it is highly questionable if this approach really
reduces unnecessary admissions. Even if different cutoff points were
adopted to rule out and rule in infarction, a gray zone of confusion
would be created, leading to considerable doubt if this strategy would
be useful in clinical practice.
